Search

Dennis P Gately

from San Diego, CA
Age ~57
Get Report
Also known as:
Denny Gately
Phone and address:
11369 Fairwind Ct, San Diego, CA 92130
(858) 755-0636
Related to:
Kelsey RempleClayton W Maher, 42Joseph SnowMichael R Heckman, 41Timothy Smith, 65Ryan Smith
Connected to:
Angela Gately, 60Audra N Gately, 47Bill Gately, 62Brendan M Gately, 47Bridget P Gately, 51Debbie A Gately, 70Denise E Gately, 68Gary W Gately, 75James C Gately, 59Jill S Gately, 56

Dennis Gately Phones & Addresses

  • 11369 Fairwind Ct, San Diego, CA 92130 (858) 755-0636
  • Elkins Park, PA
  • Groveland, MA

Work

Position: Transportation and Material Moving Occupations

Emails

d***[email protected]

Resumes

Resumes

Dennis Gately Photo 1

Dennis Gately

View page
Location:
San Diego, CA
Industry:
Biotechnology
Work:
Ambrx 2012 - 2015
Director, Cell Line Development and Associate Director, Eucode Technologies
Eli Lilly and Company 2007 - 2012
Principal Research Scientist
Eli Lilly and Company 2005 - 2007
Senior Research Scientist
Applied Molecular Evolution 2003 - 2005
Research Scientist
Idec Pharmaceuticals 2000 - 2003
Scientist Ii
Education:
Uc San Diego 1989 - 1996
Doctorates, Doctor of Philosophy, Philosophy Massachusetts Institute of Technology 1985 - 1989
Bachelors, Bachelor of Science, Biology
Skills:
Drug Development
Drug Discovery
Biotechnology
Assay Development
Antibodies
Clinical Development
Biochemistry
Biomarkers
Molecular Biology
Biopharmaceuticals
High Throughput Screening
Dennis Gately Photo 2

Dennis Gately

View page
Dennis Gately Photo 3

Dennis Gately

View page

Publications

Us Patents

Quantification Of Cellular Injury Using Expression Of A Fluorescent Protein Under The Control Of The Gadd153 Promoter

View page
US Patent:
6344324, Feb 5, 2002
Filed:
Jan 7, 2000
Appl. No.:
09/479529
Inventors:
Stephen B. Howell - Del Mar CA
Xinjian Lin - San Diego CA
Dennis P. Gately - San Diego CA
Assignee:
Research Development Foundation - Carson City NV
International Classification:
C12Q 168
US Classification:
435 6, 435 29, 435366, 435371
Abstract:
The present invention features a novel cellular injury reporter system in which a chimeric gene containing the GADD153 promoter linked to the coding region of an enhanced green fluorescent protein (EGFP) gene was stably integrated into the genome of carcinoma cells. Activation of the GADD153 promoter was quantified using flow cytometric measurement of EGFP expression following drug exposure. This reporter system is suitable for high. throughput in vitro and in vivo screening for agents capable of producing cytotoxicity via a wide variety of different mechanisms, and can be utilized to investigate the relative potency of structurally related DNA adducts.

Gene Coding For Gadd153 As A Clinical Diagnostic And Prognostic In Cancer Therapy

View page
US Patent:
6447997, Sep 10, 2002
Filed:
Jul 18, 1997
Appl. No.:
08/896406
Inventors:
Gerrit Los - San Diego CA
Dennis P Gately - Elkins Park PA
Assignee:
Research Development Foundation - Carson City NV
International Classification:
C12Q 168
US Classification:
435 6, 536 235
Abstract:
The GADD153 gene is used herein as a molecular marker for in vivo tumor cell injury which occurs in response to chemotherapy. A GADD153-based prognostic method for tumor clinical response in a patient undergoing chemotherapy is provided. By determination of the magnitude of increase, above baseline, in GADD153 mRNA in a sample derived from a tumor in a patient after administration of a chemotherapeutic agent, the method is able to predict the tumor clinical response and, thus, the patient therapeutic response. This method is advantageous over known prognostic methods for tumor clinical response in that it can accurately and rapidly predict therapeutic responses including tumor progression, partial regression and complete regression for a wide range of tumors and chemotherapeutic agents.

Prostate Specific Genes And The Use Thereof In Design Or Therapeutics

View page
US Patent:
20030235533, Dec 25, 2003
Filed:
Feb 19, 2003
Appl. No.:
10/367978
Inventors:
Dennis Gately - San Diego CA, US
Assignee:
IDEC Pharmaceuticals Corporation
International Classification:
A61K051/00
C12Q001/68
C07H021/04
C12P021/02
C12N005/06
C07K016/30
US Classification:
424/001490, 514/044000, 424/178100, 435/006000, 435/069100, 435/320100, 435/325000, 530/350000, 530/388800, 536/023500
Abstract:
Genes that are upregulated in human prostate tumor tissues and the corresponding proteins are identified. These genes and the corresponding antigens are suitable targets for the treatment, diagnosis or prophylaxis of prostate cancer. A preferred target gene is Kv3.2.

Novel Gene Targets And Ligands That Bind Thereto For Treatment And Diagnosis Of Colon Carcinomas

View page
US Patent:
20060089493, Apr 27, 2006
Filed:
Mar 28, 2003
Appl. No.:
10/509131
Inventors:
Karen McLachlan - Encinitas CA, US
Dennis Gately - San Diego CA, US
Assignee:
BIOGEN IDEC INC. - San Diego CA
International Classification:
C12Q 1/68
G01N 33/574
C07H 21/04
C12P 21/06
C07K 14/82
C07K 16/30
A61K 48/00
US Classification:
536023500, 530350000, 435006000, 435007230, 435069100, 435320100, 435325000, 530388800, 514044000
Abstract:
Nucleic acids and proteins that are overexpressed in colon or colorectal tumor tissues, and which are useful diagnostic and therapeutic targets.

Novel Gene Targets And Ligands That Bind Thereto For Treatment And Diagnosis Of Colon Carcinomas

View page
US Patent:
20080213166, Sep 4, 2008
Filed:
Nov 20, 2003
Appl. No.:
10/535458
Inventors:
Karen McLachlan - Del Mar CA, US
Dennis P. Gately - San Diego CA, US
Assignee:
BIOGEN IDEC INC. - Cambridge MA
International Classification:
A61K 51/10
C07H 21/00
C07K 16/18
C12Q 1/68
A61K 31/7105
A61K 31/711
A61K 38/00
G01N 33/53
C07K 2/00
A61K 39/395
A61P 35/00
US Classification:
424 149, 536 231, 536 2433, 5303911, 530300, 4241381, 435 6, 435 71, 435 793, 514 44, 514 2
Abstract:
Isolated nucleic acids and proteins that are overexpressed in human cancers, and antibodies that specifically bind the proteins, which are useful diagnostic and therapeutic targets.

Prostate Specific Genes And The Use Thereof In Design Of Therapeutics

View page
US Patent:
20090053227, Feb 26, 2009
Filed:
May 9, 2008
Appl. No.:
12/118455
Inventors:
Dennis GATELY - San Diego CA, US
Assignee:
Biogen Idec MA Inc. - Cambridge MA
International Classification:
C07K 16/30
G01N 33/574
A61K 39/395
A61P 35/00
US Classification:
4241381, 5303877, 5303913, 435 723
Abstract:
Genes that are upregulated in human prostate tumor tissues and the corresponding proteins are identified. These genes and the corresponding antigens are suitable targets for the treatment, diagnosis or prophylaxis of prostate cancer. A preferred target gene is Kv3.2.

Anti-Hepcidin Antibodies And Uses Thereof

View page
US Patent:
20090136495, May 28, 2009
Filed:
Oct 29, 2008
Appl. No.:
12/260125
Inventors:
Dennis Patrick Gately - San Diego CA, US
Donmienne Doen Mun Leung - San Diego CA, US
Barbara Anne Swanson - Encinitas CA, US
Ying Tang - San Diego CA, US
YuPing Anthony Cai - Carmel IN, US
LuHong He - Carmel IN, US
Peng Luan - Fishers IN, US
Derrick Ryan Witcher - Fishers IN, US
International Classification:
A61K 39/395
C07K 16/18
C12N 15/11
C12P 21/04
G01N 33/53
C12N 15/00
C12N 5/06
US Classification:
4241331, 5303873, 536 2353, 4353201, 435358, 435 696, 435 72
Abstract:
Monoclonal antibodies are provided that selectively bind human hepcidin-25 and are characterized as having high affinity for human hepcidin-25 and strong human mature hepcidin neutralizing properties. The antibodies of the invention are useful therapeutically for increasing serum iron levels, reticulocyte count, red blood cell count, hemoglobin, and/or hematocrit in a human and for the treatment and diagnosis of mature hepcidin-promoted disorders such as anemia, in a human subject.

Cellular Injury Response Element And Uses Thereof

View page
US Patent:
57704309, Jun 23, 1998
Filed:
Jun 11, 1996
Appl. No.:
8/661649
Inventors:
Stephen B. Howell - Del Mar CA
Dennis P. Gately - Philadelphia PA
Assignee:
Research Development Foundation - Carson City NE
International Classification:
C12N 500
C12N 1563
C07H 2104
US Classification:
4352402
Abstract:
The present invention provides a vector with a DNA sequence coding for a cellular injury element promoter from nucleotides -74 to -35 of the GADD153 promoter, relative to the start of transcription. The vector includes an origin of replication in operable linkage with a DNA sequence coding for the promoter. Also, a host cell is transfected with the vector and expresses the cellular injury response element promoter.
Control profile
Dennis P Gately from San Diego, CA, age ~57 Get Report